BioSpace News Archive

Latest Study on “Horseradish Peroxidase Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2022-2030”.

According to latest report study, the global Red Biotechnology market reached value at USD 357.9 Billion in 2021 and projected to hit over USD 609.8 billion by 2030.

McKesson Corporation announced that it has signed an agreement in principle to extend its partnership with CVS Health to distribute pharmaceuticals to mail order and specialty pharmacies, retail pharmacies and distribution centers through June 2027.

Imunon, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved the grant of inducement stock options to purchase a total of 8,500 shares of common stock and restricted stock grants totaling 2,250 shares of common stock as a material inducement to the employment to two individuals hired by Imunon during the third quarter of 2022.

Amylyx Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved RELYVRIO™ for the treatment of adults with amyotrophic lateral sclerosis.

InflammX Therapeutics, Inc. (InflammX), a privately held biopharmaceutical company, today announced the submission of an Investigational New Drug (IND) Amendment to U.S. Food and Drug Administration (FDA), to enable the commencement of clinical trials with Xiflam™, an orally administered NLRP3 inflammasome inhibitor with broad application that is formulated as a tablet.

Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that company leadership members will be making presentations and taking one-on-one meetings at three upcoming investor relations conferences.

Latest Study on “Adrenocorticotropic Hormone [ACTH] Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2022-2030”.

Latest Study on “CAR T-Cell Therapy Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2022-2030”.

TearClear, an ophthalmic pharmaceutical company that transforms trusted drugs into branded best-in-class therapies, announced today that the company’s lead product, TC-002 (latanoprost ophthalmic solution 0.005%) met the primary and all secondary endpoints in the CLEAR Phase 3 pivotal trial.